Jacqui Rowbottom

2.2k total citations · 2 hit papers
14 papers, 1.6k citations indexed

About

Jacqui Rowbottom is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Reproductive Medicine. According to data from OpenAlex, Jacqui Rowbottom has authored 14 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 3 papers in Reproductive Medicine. Recurrent topics in Jacqui Rowbottom's work include Lung Cancer Treatments and Mutations (7 papers), HER2/EGFR in Cancer Research (6 papers) and PARP inhibition in cancer therapy (4 papers). Jacqui Rowbottom is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), HER2/EGFR in Cancer Research (6 papers) and PARP inhibition in cancer therapy (4 papers). Jacqui Rowbottom collaborates with scholars based in United Kingdom, United States and Canada. Jacqui Rowbottom's co-authors include Gabe S. Sonke, Peter Vuylsteke, Helen Mackay, Ron H.J. Mathijssen, Jiří Špaček, David Cibula, Nicoletta Colombo, Sven Mahner, Marie Plante and Christopher Poole and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Jacqui Rowbottom

13 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

2014 426 citations Amit M. Oza, David Cibula et al. The Lancet Oncology profile →
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

2016 384 citations J.F.R. Robertson, Igor Bondarenko et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jacqui Rowbottom United Kingdom	10	1.2k	791	567	321	271	14	1.6k
L Rhoda Molife United Kingdom	18	872 0.7×	419 0.5×	836 1.5×	359 1.1×	198 0.7×	44	1.6k
Tsveta Milenkova United Kingdom	15	1.0k 0.8×	906 1.1×	467 0.8×	546 1.7×	243 0.9×	32	1.5k
Maha Hussain United States	11	1.3k 1.0×	1.4k 1.8×	942 1.7×	562 1.8×	70 0.3×	20	2.3k
Patrick G. Pilié United States	13	1.1k 0.9×	407 0.5×	1.1k 1.9×	342 1.1×	91 0.3×	43	1.8k
Lynda Grinsted United Kingdom	11	850 0.7×	730 0.9×	703 1.2×	376 1.2×	128 0.5×	19	1.4k
Miguel Martín Spain	8	1.5k 1.2×	657 0.8×	753 1.3×	511 1.6×	62 0.2×	15	1.9k
Karen Cui United States	8	1.6k 1.3×	367 0.5×	729 1.3×	820 2.6×	58 0.2×	29	1.9k
Aglaya G. Iyevleva Russia	22	588 0.5×	473 0.6×	689 1.2×	482 1.5×	112 0.4×	78	1.5k
Sarah Runswick United Kingdom	9	2.3k 1.9×	932 1.2×	1.3k 2.2×	869 2.7×	117 0.4×	18	3.0k
Lone H. Ottesen United States	18	618 0.5×	698 0.9×	646 1.1×	214 0.7×	85 0.3×	56	1.4k

Countries citing papers authored by Jacqui Rowbottom

Since Specialization

Citations

This map shows the geographic impact of Jacqui Rowbottom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacqui Rowbottom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacqui Rowbottom more than expected).

Fields of papers citing papers by Jacqui Rowbottom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacqui Rowbottom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacqui Rowbottom. The network helps show where Jacqui Rowbottom may publish in the future.

Co-authorship network of co-authors of Jacqui Rowbottom

This figure shows the co-authorship network connecting the top 25 collaborators of Jacqui Rowbottom. A scholar is included among the top collaborators of Jacqui Rowbottom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacqui Rowbottom. Jacqui Rowbottom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Meric‐Bernstam, Funda, et al.. (2022). A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select human epidermal growth factor receptor 2 (HER2)-expressing solid tumors (DESTINY-PanTumor02).. Journal of Clinical Oncology. 40(4_suppl). TPS623–TPS623. 2 indexed citations

Meric‐Bernstam, Funda, et al.. (2021). 1869TiP A phase II, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select HER2-expressing solid tumors (DESTINY-PanTumor02). Annals of Oncology. 32. S1253–S1254. 3 indexed citations

Li, Bob T., Funda Meric‐Bernstam, Soham D. Puvvada, et al.. (2021). A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of solid tumors harboring specific HER2-activating mutations (DESTINY-PanTumor01).. Journal of Clinical Oncology. 39(15_suppl). TPS3162–TPS3162. 4 indexed citations

Robertson, J.F.R., Igor Bondarenko, Ekaterina Trishkina, et al.. (2016). Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. The Lancet. 388(10063). 2997–3005. 384 indexed citations breakdown →

Bang, Yung‐Jue, Seock‐Ah Im, Keun‐Wook Lee, et al.. (2015). Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. Journal of Clinical Oncology. 33(33). 3858–3865. 219 indexed citations

Oza, Amit M., David Cibula, Christopher Poole, et al.. (2014). Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. The Lancet Oncology. 16(1). 87–97. 426 indexed citations breakdown →

Bang, Yung‐Jue, Seock‐Ah Im, Keun‐Wook Lee, et al.. (2013). Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: A randomized, double-blind phase II study.. Journal of Clinical Oncology. 31(15_suppl). 4013–4013. 31 indexed citations

Oza, Amit M., David Cibula, Ana Oaknin, et al.. (2012). Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.. Journal of Clinical Oncology. 30(15_suppl). 5001–5001. 47 indexed citations

Natale, Ronald B., Sumitra Thongprasert, F. Anthony Greco, et al.. (2011). Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 29(8). 1059–1066. 244 indexed citations

10.

Goss, Geraldine, S. Thongprasert, F. Anthony Greco, et al.. (2009). 9005 Vandetanib versus erlotinib in patients with previously treated advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial. European Journal of Cancer Supplements. 7(2). 506–506. 1 indexed citations

11.

Natale, Ronald B., S. Thongprasert, F. Anthony Greco, et al.. (2009). Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST). Journal of Clinical Oncology. 27(15_suppl). 8009–8009. 64 indexed citations

12.

Miller, Kathy D., José Trigo, Catherine Wheeler, et al.. (2005). A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer. Clinical Cancer Research. 11(9). 3369–3376. 155 indexed citations

13.

Herbst, Regina, Barry C. Johnson, Jacqui Rowbottom, et al.. (2005). O-100 ZD6474 plus docetaxel in patients with previously treatedNSCLC: Results of a randomized, placebo-controlled Phase II trial. Lung Cancer. 49. S35–S36. 22 indexed citations

14.

Heymach, John V., B. E. Johnson, Jacqui Rowbottom, et al.. (2005). A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC. Journal of Clinical Oncology. 23(16_suppl). 3023–3023. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact